Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
Authors
Keywords
-
Journal
Open Forum Infectious Diseases
Volume 8, Issue 12, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-11-18
DOI
10.1093/ofid/ofab542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
- (2021) Katharina Nickel et al. BMC INFECTIOUS DISEASES
- Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group
- (2021) Michał Łomiak et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication
- (2021) Shahini Shah et al. Current Opinion in HIV and AIDS
- Changes in BMI associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States
- (2021) Karam Mounzer et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
- (2021) Bernard Surial et al. ANNALS OF INTERNAL MEDICINE
- Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials
- (2021) Kristine M Erlandson et al. CLINICAL INFECTIOUS DISEASES
- Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan
- (2021) Naoki Kanda et al. HIV MEDICINE
- Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study
- (2021) Mostafa Shokoohi et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants
- (2021) Sebastiaan O. Verboeket et al. PLoS One
- Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV
- (2021) Jordan E. Lake et al. Current Opinion in HIV and AIDS
- Weight gain before and after switch from TDF to TAF in a U.S. cohort study
- (2021) Patrick WG Mallon et al. Journal of the International AIDS Society
- Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus
- (2021) Nathanial S Nolan et al. Open Forum Infectious Diseases
- Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
- (2021) Ana González-Cordón et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
- (2021) Mahoko Ikeda et al. AIDS Research and Therapy
- The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen
- (2020) Lucia Taramasso et al. AIDS
- Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
- (2020) Jordan E Lake et al. CLINICAL INFECTIOUS DISEASES
- Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
- (2020) C Schwarze‐Zander et al. HIV MEDICINE
- Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV
- (2020) Pere Domingo et al. INTERNATIONAL JOURNAL OF OBESITY
- Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight
- (2020) Carrie McMahon et al. PLoS One
- Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCDID Cohort
- (2020) Aoife Lacey et al. AIDS
- The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
- (2020) Jennifer Gorwood et al. CLINICAL INFECTIOUS DISEASES
- Nothing is perfect: the safety issues of integrase inhibitor regimens
- (2020) Sofía Scévola et al. Expert Opinion On Drug Safety
- Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials
- (2020) Xingbao Tao et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
- (2020) Kassem Bourgi et al. Journal of the International AIDS Society
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
- (2020) Rulan Griesel et al. CLINICAL INFECTIOUS DISEASES
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
- (2020) Michael A Leonard et al. CLINICAL INFECTIOUS DISEASES
- Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients
- (2020) Jennifer Lagoutte-Renosi et al. CURRENT HIV RESEARCH
- Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG
- (2020) F Ibrahim et al. HIV MEDICINE
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
- (2020) Willem D F Venter et al. Lancet HIV
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- (2020) Alexandra Calmy et al. Lancet HIV
- Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis
- (2020) Shailendra V Selvaraj et al. Open Forum Infectious Diseases
- Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
- (2020) Cecile D. Lahiri et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
- (2020) Nicola Squillace et al. Drug Design Development and Therapy
- Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era
- (2020) Stephanie A. Ruderman et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077
- (2019) Raphael J Landovitz et al. CLINICAL INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings
- (2019) Robin M Nance et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate
- (2019) Ana Milinkovic et al. AIDS
- Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
- (2019) Mario Cruciani et al. PLoS One
- Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
- (2019) Kai Juhani Kauppinen et al. AIDS PATIENT CARE AND STDS
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Changes in Body Mass Index and Atherosclerotic Disease Risk Score after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
- (2019) Jason J Schafer et al. Open Forum Infectious Diseases
- Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate
- (2019) Gregory D Huhn et al. Open Forum Infectious Diseases
- Weight gain and integrase inhibitors
- (2019) Allison Ross Eckard et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
- (2018) David V Glidden et al. CLINICAL INFECTIOUS DISEASES
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
- (2018) Mario Gomez et al. INFECTION
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy
- (2017) Thibaut Davy-Mendez et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir-induced hyperglycaemia in a patient living with HIV
- (2017) Milena McLaughlin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tenofovir Alafenamide
- (2016) Amanda K. Gibson et al. ANNALS OF PHARMACOTHERAPY
- Integrase strand transfer inhibitor-associated diabetes mellitus: A case report
- (2016) Peter S Fong et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
- (2016) Steve Kanters et al. Lancet HIV
- The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
- (2015) José R. Santos et al. CLINICAL INFECTIOUS DISEASES
- Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF–Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202
- (2012) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
- (2010) Marisa Tungsiripat et al. AIDS
- Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
- (2010) M. A. Valantin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Lipid-lowering effect of tenofovir in HIV-infected patients
- (2010) M. Fabbiani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search